Overview
- 23 inspections across 21 sites are on record.
- 200 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2024-12-13.
At a glance
Inspections
23
Sites
21
Observations
200
Career since
Jan 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Baxter Healthcare (Guangzhou) Co., Ltd. | 13 Dec 2024 | Human Drugs | On file |
| Baxter Healthcare (Shanghai) Co. Ltd. | 3 Dec 2024 | Human Drugs | On file |
| Rechon Life Science AB | 6 Sep 2024 | Human Drugs | On file |
| Baxter Healthcare Corporation | 19 Jul 2024 | Human Drugs | On file |
| Nang Kuang Pharmaceutical Co. Ltd. | 2 Apr 2024 | Human Drugs | View 483 → |
Sites inspected
Baxter Healthcare (Guangzhou) Co., Ltd.Guangzhou, China1 insp.
Baxter Healthcare (Shanghai) Co. Ltd.Shanghai, China1 insp.
Rechon Life Science ABLimhamn, Sweden1 insp.
Baxter Healthcare CorporationJayuya, United States1 insp.
Nang Kuang Pharmaceutical Co. Ltd.Tainan City, Taiwan1 insp.
Co-investigators
Investigators who share inspections with this person.
Walden H Lee5 shared
Amanda L Fyles3 shared
Saleem A Akhtar2 shared
Dipesh K Shah2 shared
Claudia M Perez-Kasmarski2 shared
Michael T Cyrus2 shared
Santiago Gallardo Johnson2 shared
Bryan A Galvez2 shared
Jamie L Dion2 shared
Carrie A Hughes2 shared
Full investigator report
Get the verbatim findings behind Amir Alavi's 200 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site